Castration-Resistant Prostate Cancer (CRPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The development of CRPC occurs when prostate cancer becomes resistant to standard therapies such as androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones known as androgens (such as testosterone). 10% to 20% of all cases of prostate cancer are castrate-resistant prostate cancer (CRPC). In the US, there will most likely be 268,490 new cases of prostate cancer found in 2022, and the disease will claim the lives of 34,500 men. Unknown factors increased non-Hispanic Black men's risk of prostate cancer by 73% compared to non-Hispanic White men. Changes in prostate cancer incidence rates are largely attributed to the prostate-specific antigen (PSA) blood test, which primarily detects localized stage disease. In addition to rising consumer acceptance of novel medications and an unhealthy lifestyle, market expansion is anticipated to be fueled by an increase in the incidence of castrate-resistant prostate cancer. The market's rate of growth is influenced by both the demand for quick alternative treatments and the spending on R&D by big businesses.

Description

Castrate-resistant prostate cancer accounts for 10% to 20% of all cases of the disease (CRPC). When prostate cancer develops the ability to withstand conventional treatments with androgen deprivation therapy (ADT), which inhibits the synthesis and signalling activity of hormones known as androgens (such as testosterone), CRPC develops. Only approximately 16% of CRPCs are discovered before metastasis, which means that most CRPC diagnoses are made as metastatic (mCRPC) (non-metastatic CRPC, or nmCRPC). The standard first line of treatment for men having advanced prostate cancer is androgen deprivation therapy. Orchiectomy, LHRH agonists, or a combination of an LHRH agonist and an antiandrogen are some of the other methods (complete androgen blockade). Most patients eventually develop progressive, metastatic castrate-resistant illness, even though the first hormone treatment has a high rate of patient response. Now that we know, many of these CRPC cancers still depend on androgen or AR stimulation. As a result, it is feasible that these individuals will benefit from both subsequent hormonotherapy (such abiraterone acetate) and other novel chemotherapeutic drugs or biological strategies.

Castration-Resistant Prostate Cancer (CRPC) (Epidemiology)

In the US, 34,500 men will die from prostate cancer in 2022, with 268,490 new cases expected to be discovered. For unknown reasons, non-Hispanic Black men had a 73% higher risk of developing prostate cancer than non-Hispanic White men. Changes in prostate cancer incidence rates are largely attributed to the prostate-specific antigen (PSA) blood test, which primarily detects localized stage disease. Localized-stage disease rates remained largely stable from 2014 to 2018, but rates for advanced-stage cancers rose by 4% to 6% annually. The disease's incidence remained stable from 2014 to 2018, following a decline in the late 2000s and early 2010s brought on by modifications to screening recommendations and a decrease in PSA testing.

Castration-Resistant Prostate Cancer (CRPC) -Current Market Size & Forecast Trends

The market for castration-resistant prostate cancer (CRPC) is anticipated to grow significantly, with estimates indicating a value of approximately USD 12.92 billion in 2024, projected to reach around USD 29.79 billion by 2034, reflecting a compound annual growth rate (CAGR) of 8.7% during the period from 2025 to 2034. This growth is driven by the increasing prevalence of prostate cancer, particularly among aging populations, alongside advancements in therapeutic options such as next-generation hormonal therapies, chemotherapy, and immunotherapies. North America is expected to maintain the largest market share due to its robust healthcare infrastructure and significant investments in cancer research. The ongoing development of innovative treatments and greater awareness of prostate cancer are also contributing factors, positioning the market for continued expansion through 2035.

The incidence of castrate-resistant prostate cancer is expected to increase, along with consumer acceptance of novel medications and unhealthy lifestyles. The market's growth rate is influenced by both the demand for quick alternative therapies and large companies' R&D expenditures. Rilimogene galvacirepvec (BN ImmunoTherapeutics), Seviteronel (Innocrin Pharmaceuticals), TRC 253 (Janssen Pharmaceutica), and other emerging drugs that have the potential to drive the market growth in an upward trend are among those that are already in the clinical stage of development. Castrate-resistant prostate cancer is more common than non-castrate-resistant prostate cancer, and it often progresses within a few years of diagnosis, contributing to an increase in its incidence worldwide. In the US, more than 3.6 million men were diagnosed with prostate cancer in 2020, with metastatic castrate-resistant prostate cancer (mCRPC) occurring 12.2% of the time. The rising trend of early illness diagnosis is linked to a better prognosis. Therefore, it is anticipated that these factors will accelerate market growth. Additionally, 85.0% of the demographics responded favorably to the first session of standard chemical castration therapy. Additionally, as more patient-friendly healthcare costs, like health insurance, are made available by various businesses, the market for castrate-resistant prostate cancer could expand. Another issue affecting segment development is the absence of a regular treatment sequence. These factors are expected to increase demand for castrate-resistant prostate cancer treatments.

Report Highlights

Castration-Resistant Prostate Cancer (CRPC) - Current Market Trends

Castration-Resistant Prostate Cancer (CRPC) - Current & Forecasted Cases across the G8 Countries

Castration-Resistant Prostate Cancer (CRPC) - Market Opportunities and Sales Potential for Agents

Castration-Resistant Prostate Cancer (CRPC) - Patient-based Market Forecast to 2035

Castration-Resistant Prostate Cancer (CRPC) - Untapped Business Opportunities

Castration-Resistant Prostate Cancer (CRPC) - Product Positioning Vis-a-vis Competitors' Products

Castration-Resistant Prostate Cancer (CRPC) - KOLs Insight